<?xml version='1.0' encoding='utf-8'?>
<document id="25579091"><sentence text="Evaluation of drug-drug interaction between the novel cPLA2 inhibitor AK106-001616 and methotrexate in rheumatoid arthritis patients."><entity charOffset="87-99" id="DDI-PubMed.25579091.s1.e0" text="methotrexate" /></sentence><sentence text="1" /><sentence text=" Drug interaction potential between AK106-001616, a novel cytosolic phospholipase A2 inhibitor, and methotrexate (MTX) in rheumatoid arthritis patients was investigated"><entity charOffset="100-112" id="DDI-PubMed.25579091.s3.e0" text="methotrexate" /><entity charOffset="114-117" id="DDI-PubMed.25579091.s3.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.25579091.s3.e0" e2="DDI-PubMed.25579091.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25579091.s3.e0" e2="DDI-PubMed.25579091.s3.e1" /></sentence><sentence text=" This trial is registered with ClinicalTrials" /><sentence text="gov, number NCT00902369" /><sentence text=" 2" /><sentence text=" In the clinical study, the 90% confidence intervals (CIs) for the geometric mean ratio (GMR) of AUC0-t of MTX administered after AK106-001616 200 mg compared to the MTX without AK106-001616 were within 80-125%"><entity charOffset="107-109" id="DDI-PubMed.25579091.s7.e0" text="MTX" /><entity charOffset="166-168" id="DDI-PubMed.25579091.s7.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.25579091.s7.e0" e2="DDI-PubMed.25579091.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25579091.s7.e0" e2="DDI-PubMed.25579091.s7.e1" /></sentence><sentence text=" However, administration of AK106-001616 at doses of 400 and 600 mg exceeded the 125% threshold" /><sentence text=" As small but statistically significant increases in AUC0-t were observed, we investigated the mechanism for this drug-drug interaction between MTX and AK106-001616"><entity charOffset="144-146" id="DDI-PubMed.25579091.s9.e0" text="MTX" /></sentence><sentence text=" 3" /><sentence text=" In vitro, AK106-001616 inhibited OAT1 (IC50 = 18" /><sentence text="4 μM, Ki = 33" /><sentence text="6 μM) in a non-competitive manner and OAT3 (IC50 = 1" /><sentence text="80 μM, Ki = 1" /><sentence text="49 μM) in a competitive manner" /><sentence text=" Both transporters are involved in MTX transport in renal proximal tubules"><entity charOffset="35-37" id="DDI-PubMed.25579091.s16.e0" text="MTX" /></sentence><sentence text=" 4" /><sentence text=" AK106-001616 has a weak drug interaction with MTX"><entity charOffset="47-49" id="DDI-PubMed.25579091.s18.e0" text="MTX" /></sentence><sentence text=" In vitro studies provide a mechanistic understanding of the in vivo inhibition of transporters by AK106-001616" /><sentence text="" /></document>